Equities research analysts predict that SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Rating) will report earnings of ($1.19) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for SpringWorks Therapeutics’ earnings, with estimates ranging from ($1.28) to ($0.96). SpringWorks Therapeutics reported earnings of ($0.97) per share during the same quarter last year, which would indicate a negative year over year growth rate of 22.7%. The firm is scheduled to issue its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that SpringWorks Therapeutics will report full year earnings of ($4.68) per share for the current fiscal year, with EPS estimates ranging from ($5.20) to ($3.29). For the next financial year, analysts forecast that the company will report earnings of ($4.53) per share, with EPS estimates ranging from ($5.04) to ($3.13). Zacks’ earnings per share calculations are an average based on a survey of research analysts that cover SpringWorks Therapeutics.
SpringWorks Therapeutics (NASDAQ:SWTX – Get Rating) last issued its quarterly earnings data on Thursday, May 5th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.24). During the same period in the prior year, the firm earned ($0.62) earnings per share.
Institutional investors and hedge funds have recently bought and sold shares of the business. Qube Research & Technologies Ltd raised its holdings in SpringWorks Therapeutics by 57.0% in the fourth quarter. Qube Research & Technologies Ltd now owns 8,297 shares of the company’s stock worth $514,000 after purchasing an additional 3,013 shares in the last quarter. Sphera Funds Management LTD. grew its stake in shares of SpringWorks Therapeutics by 27.1% in the third quarter. Sphera Funds Management LTD. now owns 247,917 shares of the company’s stock worth $15,728,000 after acquiring an additional 52,800 shares during the last quarter. Natixis purchased a new stake in shares of SpringWorks Therapeutics in the third quarter worth $2,119,000. Credit Suisse AG grew its stake in shares of SpringWorks Therapeutics by 19.0% in the third quarter. Credit Suisse AG now owns 14,809 shares of the company’s stock worth $939,000 after acquiring an additional 2,367 shares during the last quarter. Finally, Ensign Peak Advisors Inc grew its stake in shares of SpringWorks Therapeutics by 27.1% in the third quarter. Ensign Peak Advisors Inc now owns 82,161 shares of the company’s stock worth $5,212,000 after acquiring an additional 17,527 shares during the last quarter. Institutional investors and hedge funds own 96.20% of the company’s stock.
Shares of NASDAQ SWTX traded up $0.45 during midday trading on Thursday, hitting $35.34. 562,929 shares of the company’s stock were exchanged, compared to its average volume of 460,249. SpringWorks Therapeutics has a 12-month low of $33.33 and a 12-month high of $89.75. The company has a market cap of $1.75 billion, a price-to-earnings ratio of -8.37 and a beta of 1.01. The business’s fifty day moving average price is $53.18 and its two-hundred day moving average price is $59.61.
SpringWorks Therapeutics Company Profile (Get Rating)
SpringWorks Therapeutics, Inc acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors.
- Get a free copy of the StockNews.com research report on SpringWorks Therapeutics (SWTX)
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
- The S&P 500 Could Fall Another 28%
- Corning Stock is a Technology Value Play
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.